(ECOR) electroCore, Inc. Marketing Mix Research |
Fully Editable: Tailor To Your Needs In Excel Or Sheets
Professional Design: Trusted, Industry-Standard Templates
Investor-Approved Valuation Models
MAC/PC Compatible, Fully Unlocked
No Expertise Is Needed; Easy To Follow
(ECOR) electroCore, Inc. Complete Analysis Pack
See the Bigger Picture
This electroCore, Inc. 4P's Marketing Mix Analysis explains the company’s product offering (non-invasive neuromodulation devices), its clinical and commercial uses, and shows how pricing, distribution, and promotion align with market needs; this page contains a real preview/sample of the analysis so you can review content and style—purchase the full version to get the complete ready-to-use report.
Product
gammaCore Sapphire device
gammaCore Sapphire is electroCore, Inc.’s flagship portable neuromodulation device and the core product in its commercial portfolio. It is a non-invasive vagus nerve stimulation device cleared in the U.S. for acute and preventive use in headache care, including migraine and cluster headache. In 2025, electroCore reported net revenue of $31.3 million, showing the device remains central to sales.
nVNS therapy platform
electroCore, Inc. nVNS therapy platform uses non-invasive vagus nerve stimulation, so it is a device-based therapy, not a drug. It sits at the core of the Company Name medical device model and supports repeat-use treatment for headache and other neurologic uses.
The platform is built for home and clinic use, with FDA-cleared gammaCore therapy spanning multiple indications, including cluster headache and migraine prevention.
Acute migraine treatment
gammaCore is an adult, episodic-use device for acute migraine relief, meant to ease discomfort at the time of an attack. Its product value is in fast, on-demand symptom treatment rather than daily prevention, which fits patients who need non-drug rescue options. In the latest disclosed filings, electroCore kept gammaCore as its core neuromodulation brand for migraine and cluster-headache use.
Episodic cluster headache treatment
electroCore’s gammaCore is also cleared for episodic cluster headache in adults, so the product goes beyond migraine and addresses a second, high-need pain market. Cluster headache affects about 0.1% of people, and episodic cases make up most diagnoses, which keeps the use case focused but clinically important. In electroCore’s 2025 filings, this broader label supported a larger commercial base for the Company.
- Adult episodic cluster headache use
- Broadens beyond migraine
- Targets a rare, severe condition
Portable rechargeable refillable design
electroCore, Inc.'s Sapphire device is built for portable, rechargeable, refillable use, so patients can use it regularly or only when needed over many years. That design lowers replacement needs and supports long-term adherence, which matters in a chronic-therapy product. In the 2025 reporting cycle, the product story is less about one-time sales and more about repeat use and durable customer engagement.
- Portable for use anywhere
- Rechargeable for repeated use
- Refillable for long-term therapy
- Built for years of use
gammaCore Sapphire Drives electroCore’s 2025 Revenue Growth
electroCore, Inc.’s product mix centers on gammaCore Sapphire, a portable, non-invasive vagus nerve stimulation device for acute and preventive migraine and cluster headache care. In 2025, electroCore reported net revenue of $31.3 million, showing the device stayed the core sales driver. The product is reusable, home-based, and built for repeated long-term use.
| Product | Core use | 2025 fact |
|---|---|---|
| gammaCore Sapphire | Migraine and cluster headache | Net revenue: $31.3 million |
What is included in the product
Detailed Word Document
Provides a concise, company-specific 4P’s Marketing Mix analysis of electroCore, Inc.’s Product, Price, Place, and Promotion strategy.
Editable Excel File
Condenses electroCore’s 4Ps into a quick pain-point snapshot, helping teams spot and address customer needs fast.
Reference Sources
Provides a concise, traceable list of primary sources (clinical trials, FDA filings, SEC reports, and industry analyses) to speed due diligence and validate electroCore, Inc. assumptions.
Place
Rockaway, New Jersey headquarters
electroCore, Inc. is headquartered in Rockaway, New Jersey, and that site is the company’s main corporate location in its profile. It anchors the commercial and operating base for the business.
For marketing mix, the HQ matters because it centralizes leadership, investor relations, and operating control close to the company’s U.S. core.
Prescription channel access
gammaCore is prescription-only, so electroCore, Inc. does not sell it through normal OTC retail; access starts with a clinician script. That makes "place" a healthcare channel game, centered on neurology, headache, and pain clinics, plus telehealth and payer-linked pathways. The model also narrows reach versus shelves, but it can support better patient selection and adherence.
Adult patient use setting
electroCore, Inc.'s gammaCore is intended for adults, with use studied in patients 18 and older. The handheld, portable design lets patients use it at home, at work, or while traveling after prescription and training.
That matters because access is practical outside a clinic, which supports routine use in varied patient settings. In adult studies, treatment is delivered in short sessions, making it easier to fit into daily care.
For the 4P place mix, the product reaches patients through trained prescribing clinicians, then moves with them in a compact device, not a fixed site.
Commercial-phase market availability
electroCore is in the commercial phase, so Place is about reaching patients and providers, not just making the device. That means channel access, payer coverage, and fulfillment matter as much as production. In practice, the company must keep product available through health systems, distributors, and direct patient delivery.
- Commercial phase: market access drives sales
- Fulfillment and coverage shape availability
- Distribution supports patient reach
Long-term device reuse
electroCore, Inc.'s reusable device format is built for multi-year use, so one unit can stay in the distribution channel longer and need fewer swaps. That lowers replacement pressure and supports a Place strategy built around durable access, not fast hardware turnover. In FY2025, this matters because the model favors repeat use and ongoing demand over one-time device moves.
- Multi-year device life
- Fewer replacements needed
- Lower channel turnover
- Supports durable distribution
Prescription-Only Relief, Controlled from Rockaway
Place for electroCore, Inc. is a controlled healthcare channel: gammaCore reaches patients through clinicians, not retail shelves, and then is used at home or on the move after prescription and training. Its Rockaway, New Jersey base supports U.S. commercial, payer, and fulfillment control.
| Place factor | Data |
|---|---|
| Access route | Prescription-only |
| Use setting | Home, work, travel |
| HQ | Rockaway, New Jersey |
| Target use | Adults 18+ |
What You See Is What You Get
electroCore, Inc. Reference Sources
The preview shown here is the actual document you’ll receive instantly after purchase—no surprises. This ElectroCore, Inc. 4P's Marketing Mix Analysis covers Product, Price, Place, and Promotion with actionable insights, competitive context, and concise recommendations tailored for investors and strategists.
Promotion
Non-invasive therapy message
Promotion centers on non-invasive vagus nerve stimulation, so electroCore, Inc. stands apart from drug-based headache therapies. The device-led message fits patients who want treatment without pills, which also supports repeat use across migraine and cluster headache care. That positioning is clear in electroCore, Inc.’s cash-focused model, with FY2024 revenue of about $26 million.
Migraine indication focus
electroCore, Inc. centers promotion on adult acute migraine treatment, which targets a huge, familiar headache market. Migraine affects about 1 in 7 people worldwide, or roughly 1 billion people, so the indication makes the audience and medical message clear. This focus helps gammaCore speak directly to adults who need fast, non-drug migraine relief.
Cluster headache indication focus
electroCore, Inc. keeps episodic cluster headache at the center of its promotion because gammaCore has a second FDA-cleared use case, alongside migraine. That matters in a rare disease market that affects about 1 in 1,000 adults, and it helps build awareness with headache specialists and patients who need fast, non-drug options.
Prescription-only positioning
gammaCore is prescription-only, so electroCore, Inc. must win clinicians first, not just patients. In its latest annual filings, electroCore, Inc. reported about $27 million in annual revenue, and that makes HCP trust and medical proof central to promotion. The message has to be clinical, simple, and backed by outcomes data.
- Clinicians drive adoption.
- Medical credibility matters most.
- Sales depends on awareness.
Portable long-use value proposition
electroCore, Inc. can promote Sapphire as a portable, rechargeable, and refillable device that fits daily use and repeat use. The message should focus on convenience, durability, and lower hassle versus disposable options, so users see long-term value in one device built for regular routines.
- Portable for use at home or on the go
- Rechargeable for repeated sessions
- Refillable to support long-term use
electroCore Bets on Clinician Trust in a Huge Headache Market
electroCore, Inc. promotes gammaCore with a clinic-first message: non-invasive, drug-free relief for acute migraine and episodic cluster headache. That matters in a market of about 1 billion migraine patients and about 1 in 1,000 adults with cluster headache. With about $27 million annual revenue, clinician trust and proof of benefit drive sales.
| Metric | Value |
|---|---|
| Migraine prevalence | About 1 billion people |
| Cluster headache | About 1 in 1,000 adults |
| Annual revenue | About $27 million |
Price
No public price stated
No public list price is stated for electroCore, Inc., so the exact July 2026 price cannot be confirmed here. The company’s pricing view is qualitative only, with no disclosed MSRP or unit price in the supplied facts. That limits this 4P analysis to positioning and channel logic, not hard price data.
Reusable over many years
electroCore, Inc.'s device is designed for use over many years, so the price reflects a durable, long-life product rather than a short-cycle consumable. That supports a higher value view because buyers can spread the upfront cost across years of use, which can lower the effective cost per treatment. In the US, about 58% of adults used some form of digital health tool in 2025, which supports demand for reusable care devices.
Rechargeable device economics
gammaCore Sapphire is rechargeable, so users avoid buying a new single-use unit each time. That lowers the total cost of use and makes the price-to-value case stronger, especially for a therapy device meant for repeated treatment. For electroCore, Inc., the value story is not just the upfront price; it is the lower replacement burden over time.
Refillable product design
electroCore, Inc.'s refillable design supports repeat use, so pricing is tied to recurring supply needs rather than a one-time sale. That fits ongoing patient therapy and can lift lifetime value per customer, especially when a device is reused across multiple treatment cycles.
- Refillable format = recurring demand
- Better fit for ongoing patient use
- Supports repeat revenue over time
Prescription medical device model
electroCore, Inc.'s prescription-only model means price is set less by retail demand and more by payer access, clinician sign-off, and reimbursement terms. In FY2025, that channel-driven setup kept pricing tied to medical distribution, so adoption depends on coverage and prescription volume, not shelf pricing.
- Prescription-only access
- Payer coverage drives price
- Clinician authorization is key
- Medical channels shape pricing
electroCore pricing: no public list, lower treatment costs
electroCore, Inc. does not disclose a public list price, so FY2025/FY2026 price cannot be verified here. Its pricing is driven by reimbursement, clinician access, and prescription volume, not retail shelf pricing. The rechargeable, reusable gammaCore model supports a lower cost per treatment over time.
| Price factor | FY2025/FY2026 view |
|---|---|
| Public list price | Not disclosed |
| Buying model | Prescription, payer-led |
| Device use | Rechargeable, reusable |
| Value driver | Lower cost per treatment |
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.